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Gastroesophageal reflux disease (GERD) is a common condition, and it is now
generally recognized that modem medical therapy allows the physician to both
heal the esophagitis and relieve the patients from troublesome symptoms such
as heartburn, acid regurgitation and disabling chest pain. In addition, long-term
therapy with potent acid inhibitory drugs can maintain these patients in clinical
remission. The indications for antireflux surgery and long-term medical thera-
py have developed and changed with time but are today essentially similar, and
in fact, it can be hypothesized that the outcome of a short-term "therapeutic tri-
als" with the proton pump inhibitor would be a useful clinical tool, not only as
a diagnostic test for the disease but also in the selection process before refer-
ring the patient to antireflux surgery. Antireflux surgery is designed to improve
the function of the antireflux barrier by reconstructing the physiology of the
gastroesophageal junction. Studies have shown that a fundoplication procedure
improves the strength and length of the lower esophageal sphincter and also
restitutes the flutter valve mechanism. However, since gastroesophageal reflux
disease is a common disorder, it is impossible for every patient to be attended
by an expert surgeon, and this might be one important reason for the some-
times poor results presented after surgical treatment.
When the question arises about which type of long-term therapy should be
chosen in each clinical situation, this situation should also partly be influenced
by some epidemiological information. Ifwe assume that we expose a hypothet-
ical group of 100 patients with symptomatic, chronic severe reflux disease,
also presenting endoscopic evidence of esophagitis of varying severity, avail-
able clinical information would suggest that only 25 can be considered suitable
for antireflux surgery, depending on the frequently associated complicating
medical disorders and the age distribution of the actual patient population.
Therefore, it deserves to be emphasized that the majority ofpatients with com-
plicated reflux disease are not fit for surgery and should consequently be man-
aged medically. For younger patients with disabling GERD, antireflux surgery
is still the gold standard and obviously very cost effective.
INTRODUCTION
Recent advances in the medical treatment of gastroesophageal reflux disease
(GERD)b now allows the physicians to both heal acute episodes ofesophagitis and main-
tain these patients in clinical remission [1]. It is also generally accepted that medical
therapy can be used as a long-term maintenance therapy and may also be a legitimate
alternative to surgery for the management of severe, long-standing GERD. A compre-
hensive assessment ofthe relative merits ofthe different treatment options requires, how-
ever, generally accepted criteria for the assessments of the severity of GERD with
respect both to symptoms and/or the presence ofcomplications. In the medical literature,
aTo whom all correspondence should be addressed: Lars Lundell, M.D., Ph.D., Department of
Surgery, Sahlgren's Hospital, S-413 45 Gothenburg, Sweden. Tel: (46) 31-60-20-77; Fax: (46) 31-
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there is a general agreement on the designs of studies to be used in clinical science,
allowing the assessment of treatment outcomes (such as endoscopic healing and symp-
tom relief) and forming the basis ofan objective comparison between different drug regi-
mens. A corresponding consensus on the design of clinical trials over the efficacy of
antireflux surgery is unfortunately not available. Despite these methodological obstacles,
which complicate a comprehensive, comparative analysis, the aim of the present review
is to present the merits ofmedical and surgical therapy per se and to put these therapeutic
alternatives in the context of the epidemiology, natural history and complications of the
disease.
THE EFFICACY OF MEDICAL TREATMENT OF GERD
The main priority of any treatment based on a proper diagnosis of GERD is to con-
trol symptoms arising directly from esophageal mucosal contact with refluxed contents
of predominantly gastric nature [2]. Control of esophagitis produced by peptic injury to
the esophageal mucosa is a more long-term aim of therapy. When assessing different
clinical trials, endoscopic healing rates have been used [3] as an estimate of efficacy,
also with the addition of data on complete symptom relief (resolution) of major reflux
symptoms. The three general classes of medication used in similar therapy of reflux
esophagitis are antisecretory drugs, prokinetic agents and mucosal coating compounds.
A relationship exists between the degree of inhibition of gastric acid secretion
induced by various drugs and the subsequent capacity of these to heal the esophagitis.
This correlation is explained by the linear relationship between the per cent enhancement
of gastric pH and the percentage of time during which the intra-esophageal pH is
observed to be above 4 [4, 5]. Consequently, the clinical experience with the most effec-
tive acid inhibitory drugs, i.e., proton pump inhibitors, reveals that there are essentially
very few patients resistant to this type ofmedical treatment (Table 1) [6-18].
Table 1. Proportion of GERD patients kept in endoscopic and clinical remission (symptom
free) during maintenance treatment with omeprazole (Ome) or ranitidine (Ran) [6, 7, 9, 12,
14, 17].
Study drug n Endoscopic remission (%) Symptom free (%)
Ome (20 mg) 361 82.4 80.8
Ome (10 mg) 225 71.9 64.1
Ran (150 mg x 2) 179 52.3 52.0
Placebo 146 10.6 20.7
The success of short-term medical therapy in patients with reflux esophagitis essen-
tially depends on two factors: one is the pretreatment severity ofthe erosive and/or ulcer-
ative lesions in the esophagus and the other is the choice ofdrug therapy. However, irre-
spective ofthe type ofinitial drug therapy, patients will relapse frequently after cessation
of treatment. The slope of this relapse curve might be dependent on the pretreatment
severity of the esophagitis as well, but other factors of clinical importance may also be
operating.
The fact that the slope of the relapse curve is very steep suggests that reflux
esophagitis is, in many cases, a chronic disease, and the esophagitis with associated
symptoms will recur irrespective ofthe type of initial healing therapy. In fact, in patients
with esophagitis, the relapse rate is as high as 50-80 percent within the first 6-12 months
after stopping treatment. A low-dose maintenance treatment with H2-receptor antagonists
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(half the dose required to heal the peptic lesions), a therapeutic principle which is effec-
tive in preventing recurrent peptic ulcer disease, has not proven to be effective in reflux
esophagitis [19, 20]. On the other hand, by use of higher and more frequent doses of
H2-receptor antagonists, relapses can be prevented. The number of studies reporting an
overwhelming efficacy of omeprazole (the first synthesized proton pump inhibitor) as a
maintenance therapy for reflux esophagitis is increasing (Table 1). Even in patients with
more severe grades ofesophagitis, 20 mg ofomeprazole daily has proven adequate in all
but aminority ofpatients.
The eventual role ofprokinetic agents (the most widely used being cisapride) seems
to be in patients with milder forms of the disease, but it should be noted that a high
placebo remission rate has been observed in these trials (Table 2) [21-23]. The initial
severity ofthe endoscopic lesions, as well as the type oftherapy chosen, has a significant
impact on the number of patients who could be kept in remission during maintenance
long-term therapy.
Table 2. Proportion of GERD patients kept in endoscopic and clinical remission in trials
evaluating the long-term efficacy ofcisapride (cis.) [21, 22, 23].
Endoscopic Endoscopic Symptom
grading Study drug n healing (%) free (%)
*2 Cis. lOmgx2 37 80 81
* 2 Placebo 43 61 63
All Cis. 20mgx 2 147 58 45
All Placebo 151 47 21
1 Cis. 20 mg x 2 51 73 No data
I Placebo 51 53 No data
All Cis. 20 mg noct 151 68 56
All Cis. lOmgx2 149 66 63
All Placebo 143 49 42
1 Cis. 20 mg noct 55 90 No data
I Cis. lOmgx2 60 77 No data
I Placebo 53 58 No data
Oesophageal complications of reflux esophagitis consist primarily of bleeding,
ulceration, formation of stricture and the development of columnar lined esophageal
mucosa (Barrett's esophagus). Peptic stricture and Barrett's esophagus are not only the
major but also the most common serious complications of the disease [24]. The clinical
problems related to these manifestations are highly significant, and in patients with pep-
tic stricture, the resulting dysphagia can be a major disability that causes nutritional
problems. Dilatation of a stricture exposes the patients to a small but significant risk of
esophageal perforation. Barrett's esophagus per se rarely causes morbidity but carries a
significant risk of developing esophageal adenocarcinoma with its attended morbidity
and mortality. The primary, long-term aim of medical therapy for patients with peptic
stricture and Barrett's esophagus is the abolition of reflux symptoms and prevention of
immediate risk of recurrence or progression of complications. Prevention of progression
is thought to be achieved by healing oferosive or ulcerative lesions. The need for repeat-
ed dilatation in patients with peptic stricture is considerably lower in those undergoing
fundoplications than in those treated conservatively (i.e., with antacid or H2-receptor
antagonists) [24]. In fact, no prospective, controlled, randomized study has been presented
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to show a reduction in repeat dilatation with the use ofH2-blockers [25, 26]. Omeprazole
has the potential to produce clinical responses similar to that seen after successful antire-
flux surgery due to its effect on acid reflux into the esophagus. Results from on-going tri-
als with omeprazole in patients with peptic strictures have presented very promising pre-
liminary results, showing that the clinical aims can be fulfilled [27, 28].
When studying patients with Barrett's esophagus and the clinical response to differ-
ent therapeutic interventions, a clear distinction must be made between healing of the
esophagitis and regression of the metaplastic epithelium. Initial healing of the erosive
and/or ulcerative lesions in the squamous epithelium has been accomplished with high
doses of H2-receptor antagonist therapy, but such a regimen is not an attractive long-term
therapeutic option for the prevention of relapse of reflux symptoms and esophagitis due
to the need for very high doses and frequent dosing. Recently, a number of case reports
have been published and demonstrated remarkable symptomatic response in patients
with Barrett's esophagus when treated with omeprazole [24]. Medical therapy has not, so
far, been shown to induce any major and significant changes in the length of the colum-
nar lined segment [29, 30]. In addition, it should always be born in mind that patients
with Barrett's esophagus, in whom reflux is controlled either medically or surgically,
must undergo regular surveillance for the development ofdysplastic or neoplastic lesions
in the metaplastic epithelium [31].
"ALKALINE REFLUX"?
The role of acid and pepsin in the pathogenesis of GERD and its complications is
well documented, but the importance of refluxed alkaline duodenal contents is a contro-
versial issue. Animal studies have suggested that bile acids are injurious to the
esophageal mucosa [32, 33], and the following circumstantial, clinical evidence for the
role of these compounds in the pathogenesis of reflux complications have been obtained
from human studies: a) bile reflux causes heartburn; b) esophagitis can occur in the pres-
ence of atrophic gastritis associated with pernicious anemia and after total gastrectomy;
and c) increased amounts of duodenogastric reflux have been reported in patients with
esophagitis compared to those without esophagitis, and particularly in those with severe
complications of the disease such as strictures and columnar lined esophagus [34, 35].
During ambulatory 24-hr pH-monitoring, rises in pH above 7 occur infrequently and
have been alleged to be caused by duodenogastric reflux. However, recent reports have
suggested that these pH-raises are more likely the result of local factors in the esophagus
[36] such as bicarbonate production, swallowed saliva, etc., and not due to pure alkaline
gastroesophageal reflux as initially suggested [34, 35, 37]. On the other hand, conjugated
bile acids can be detected in the gastricjuice in 75 percent ofreflux patients, particularly
when collected at night, but on the other hand, only two percent of esophageal aspirates
contained concentrations of these compounds, which would increase the esophageal
mucosal permeability. Taken altogether, it seems as if hydrogen ions and pepsin, proba-
bly acting synergistically, are the most important components of the refluxate with the
potential to cause clinically relevant esophageal mucosal damage. In addition, reduction
in acid output and consequent elimination ofacid exposure in the esophagus also concur-
rently reduced the alkaline refluxate in the esophagus. Thus, different arguments have
been raised as to the type of therapy to be recommended in patients with alleged duo-
denogastroesophageal reflux (i.e., antireflux surgery and the creation of a competent
antireflux mechanism or medical therapy in the form ofpotent acid inhibition). One way
of reaching an opinion on this issue is to consider the efficacy by which these different
therapeutic principles have been documented to induce a regression of established
Barrett's epithelium or resolution of strictures. In fact, areasonably-well established, but
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still unpredictable, regression ofthe columnar lined mucosa seems to occur at a similarly
small frequency irrespective ofthe type oftherapy instituted [29-30, 39-40].
POTENTIAL SIDE-EFFECTS
All of the drugs that might be used for long-term maintenance therapy have proved
to be remarkably safe in short- and intermediate long-term use. However, the theoretical
disadvantages associated with long-term medical therapy may be grouped into three
classes:
1. Side-effects that are specific for the drug itself
2. Side-effects that are secondary to long-term suppression ofacid secretion.
3. Effects attributable to suboptimal treatment ofthe underlying gastroesophageal
reflux disease.
Although infrequently seen, cisapride occasionally may produce intolerable diar-
rhea, necessitating withdrawal oftherapy. H2-receptor antagonists have a very good safe-
ty record even when used long-term [41]. Omeprazole has a very low incidence of
side-effects quite comparable to that of H2-blockers [42]. During the early experience
with H2-blockers, and now also with the clinical use of proton pump inhibitors, it has
been argued that the use of similar substances might cause severe diarrhea. This is seen
particularly in underdeveloped countries due to superimposed enteric infections, alleged-
ly caused by the lack of acid in the stomach. The wide-spread clinical use of acid
inhibitory drugs, including omeprazole, all over the world has not confirmed this hypo-
thetical potential adverse consequence ofthe use ofsimilar drugs.
Bacterial overgrowth in the stomach, nitrosamine formation, hypergastrinaemia and
enterochromaffin-like cell formation are all potential hazards, which may follow
long-term potent acid suppression. The present state of knowledge does not, however,
support the notion that omeprazole or the H2-receptor antagonists currently available
have any of these serious long-term side-effects. Proton pump inhibitors produce a slight
to moderate hypergastrinaemia during acute treatment, which remains during continued
therapy [43]. Follow-up ofpatients who have taken omeprazole for five years has shown
a slight increase in mean argyrophilic cell volume density, which may be influenced both
by the natural development of chronic gastritis but also by the enhanced gastrin release.
However, no dysplastic or neoplastic endocrine cell lesions have been recorded [44].
It has been argued that long-term medical maintenance therapy may abolish symp-
toms without healing esophagitis and thus permit the progression of the asymptomatic
esophageal lesions, to the extent that severe complications may occur in the form of
stricture, Barrett's esophagus and ultimately carcinoma. Few if any data, however, sup-
port this hypothesis, and on the contrary, good symptom relief with potent antisecretory
agents seems to be closely associated with the resolution of the esophageal lesions [45].
It must, however, be remembered that a comprehensive and really firm view on the fre-
quency of side-effects on really long-term medical therapy has to wait at least another
five years, when the data from the surveillance program currently in clinical use have
been analyzed.
ANTIREFLUX SURGERY
Antireflux surgery is designed to improve the function ofthe gastroesophageal junc-
tion and to provide the GERD-patients complete relief of all symptoms and complica-
tions ofreflux disease, all ofwhich occur secondary to deficiencies in the reflux prevent-
ing barrier located in that area [46]. Ideally, reconstruction of the physiology of the gas-
troesophagealjunction should also permit the patient to swallow normally, belch to relief
distension, but hardly to vomit. A major effect of fundoplication operations has been
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shown to be a substantial reduction in the number oftransient lower esophageal sphincter
relaxations [47]. In addition, the proportion ofthese relaxations accompanied by reflux is
decreased, as well as a concomitant increase in the residual pressure at the gastroe-
sophageal junction during sphincter relaxation [47]. This is probably another additional
important mechanism to prevent reflux, especially in cases with severe complications of
the disease [48]. Previous data have repeatedly shown that fundoplication operations
restrain the lower esophageal sphincter relaxations during water swallows by what seems
to be a purely mechanical effect [49-54]. The mechanism by which fundoplications inter-
fere with the triggering of transient sphincter relaxations has, however, yet to be defined.
The prevention of reflux during complete lower esophageal sphincter relaxation, even
after a fundoplication, suggests that there are other effects of fundoplication on sphincter
function separate from that of a simple external cuff. In vitro and in vivo studies have
shown that the sphincter length contributes to sphincter competence and that fundoplica-
tion increases the length of the sphincter exposed to intra-abdominal pressure [55].
Undoubtedly, these operations also produce a simple, one-way mechanical flap or flutter
valve.
At the time of Allison's original report [56], surgical attention was on the anatomi-
cal defect in the hiatus forming the hernia rather than the problem of a physiological
defect ofincompetence in the reflux preventing mechanisms within the gastroesophageal
junction. Consequently, operations that anatomically repaired only the hiatus and the her-
nia were not successful [57]. Nissen discovered that a fundic wrap prevented reflux when
he studied a patient many years after partial esophagectomy [58]. Fundoplication has
subsequently become the most widely used form of antireflux surgery, and the efficacy
has been established by clinical and endoscopic follow-up and also by esophageal 24-hr
pH-monitoring [46, 59]. Over the last three decades, a number of modifications of the
original fundoplication operation have evolved, but not every surgeon using the actual
technique is as satisfied with the clinical outcome as the originator [60, 61].
Gastroesophageal reflux disease is such a common condition that it is impossible for
every patient to be attended by an expert, and this might be one important reason for
some of the poor results. It is clear that the overwhelming majority of studies report good
to excellent results in the order of 80 percent or better. To obtain a comprehensive view
on the clinical outcome of different antireflux procedures, data must be compiled from
controlled, clinical trials. By doing that, it can be concluded that obvious clinical differ-
ences in the efficacy between different antireflux procedures seem not to be prevailing
when the outcome is judged with regard to the cumulative GERD relapse rate (evaluated
endoscopically and/or symptomatically) [53, 62-68] (Table 3). Excellent control of gas-
troesophageal reflux symptoms can be obtained with a total fundic wrap, a 2700 fundo-
plication, 1800 fundoplication or Hill posterior gastropexi, provided that each operation
involves the reduction of hiatal hernia coupled with the construction of the valve mecha-
nism to re-establish gastroesophageal competence. It must be emphasized that these suc-
cess rates can and should be achieved with negligible mortality and morbidity. The prob-
lem is, however that published results usually represent the best results in the field of
antireflux surgery, and the local level ofexpertise can vary considerably.
Accordingly, it is reasonable to propose that antireflux surgery should be performed
only in centers, where the expertise has been assembled in the management of gastroe-
sophageal reflux disease as well as in the essential diagnostic facilities. Data are now
accumulating to show that the outcome after laparoscopic fundoplication is as advanta-
geous as that following open surgery. Long-term data after the former procedures are,
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Table 3. The clinical outcome of different antireflux procedures when evaluated in prospec-
tive, controlled, randomized clinical trials.
Follow-up Excellent to Failure
References period Procedure good results (%) rate (%)
Washer et al. (1984)
DeMeester et al. (1974)
Gear et al. (1984)
Stuart et al. (1989)
5 years
30 - 696 days
1-2 years
38 months
Nissen (360)
Roux-en-Y
Hill
Nissen (360)
Belsey (270)
Angelchik
Nissen (360)
Angelchik
Nissen (360)
65%
91%
20%
41%
47%
100%
80%
96%
81%
77%
94%
53%
0%
27%
4%
19%
23%
6%
Hill et al. (1994)
Kmiot et al. (1991)
Thor, Silander (1989)
Lundell et al. (1991)
Walther et al. (1992)
Janssen et al. (1993)
Lundell et al. (1994)
7 years Angelchik
Nissen-Rossetti (360)
3-24 months Angelchik
Nissen
5 years
6 months
13 months
12 months
4 years
Nissen (360)
Toupet (180-200)
Nissen-Rossetti (360)
Toupet (180-200)
Nissen (360)
Lind (300)
Nissen (360)
Lig. teres
gastropexi
Nissen-Rossetti (360)
Toupet (180-200)
77%
88%
60-72%
85-88%
67%
95%
95%
95%
92%
96%
90%
40%
96%
94%
however, warranted [69-70]. A technique that largely eliminates the inter-surgeon varia-
tion in technique is the introduction of the Angelchik prosthesis. This operation has been
shown to be an effective operation for controlling reflux. In the controlled clinical trials
presented so far, this procedure has been shown to be as effective as Nissen fundoplica-
tion in preventing reflux symptoms [63-65]. The disadvantages with the prosthesis are
the risk of dysphagia and migration of the prosthesis [71]. Consequently, this technique
is not to be recommended. It should always be born in mind that adequate and sustained
reflux control can essentially always be accomplished by an experienced surgeon taking
the advantage ofwrapping the mobile gastric fundus around the distal esophagus.
Unless there is a clear indication for a thoracic approach, the choice of the abdomi-
nal route is to be preferred [46, 59]. The thoracic procedure takes twice as long to
accomplish as a transabdominal fundoplication, and major postoperative problems seem
to be more frequent and are specific for the repair such as post-thoracotomy pain.
Although antireflux surgery is generally very effective in controlling gastroe-
sophageal reflux, some failures are proven unavoidable. Persistent postprandial adverse
23%
8%
28%
12%
25%
0%
3%
3%
8%
4%
0%
60%
11%
6%
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symptoms (in the form of dysphagia, inability to belch and vomit, postprandial fullness,
bloating and pain and sometimes socially embarrassing flatulence) can mar an otherwise
excellent result in a small but significant group of patients after similar procedures
[72-73]. The frequency by which these postfundoplication symptoms have been reported
varies considerably between series, from as low zero percent up to 40 percent. Dysphagia
is frequently reported during the early postoperative period but vanishes with the passage
of time. Except for dysphagia, these complaints have been assembled under the clinical
syndrome named "gas bloat." It should, however, be emphasized that patients very often
rate their postprandial symptoms as of doubtful clinical significance and very much less
than the preoperative reflux symptoms [74]. Another significant clinical observation is
that postfundoplication symptoms, as well as gas bloat symptoms, improve with the pas-
sage of time. Some clinical studies even report an impressive number of patients being
able to vomit postoperatively, especially when interviewed after many years [75-78].
Similar clinical information should, however, cause concern regarding an eventual dis-
ruption of the wrap rather than an example of subsidence of complaints with the passage
of time. Since we lack effective treatment of established, severe postfundoplication
symptoms, prevention is a primary concern. A number of technical considerations have
been focused on and alleged to counteract some of these problems, but it must be con-
cluded, based on data from controlled, randomized clinical trials, that, as yet, no signifi-
cant differences with regard to postfundoplication symptoms have been firmly estab-
lished among different antireflux procedures. There is a widespread consensus, however,
among experienced surgeons that ifa complete (3600) wrap is done it has to be both flop-
py and short, which means that the gastric fundus has to be widely mobilized and the
fundoplication done only 1 cm long [79-81]. However, a tendency has been reported in
some trials that semifundoplication procedures seem to be associated with less trouble-
some complaints [53, 67].
Failure of the floppy fundoplication to control reflux symptoms occurs in four to
nine percent of patients. There are reports with a considerably higher failure rate, and it
is important to emphasize that essentially all failures occur early in the postoperative
period, indicating the importance of adhering to technical details [82-88]. Ideally,
follow-up should be carried out by an independent assessor or by means of a detailed
performa and by objective data. Postoperative endoscopic examination is valuable, and
the follow-up period should last at least five years. Surgeons, who undertake this surgery
need to agree on standardized operative methods and objective criteria to define success,
thereby allowing an agreement on classification of anatomical, pathological and endo-
scopic features of the disease and the consequences of adequate long-term control of the
disease [89]. Studies have been published in which conventional medical therapy has
been compared to antireflux surgery [90-92]. Recently, Spechler and co-workers [93]
confirmed the superiority of antireflux surgery over traditional medical therapy to treat
complicated GERD in older male veterans. Further studies, however, are needed to
address this issue, not only in women and non-veteran populations, and available data
would thus suggest the importance of antireflux surgery as still occupying the position as
being the gold standard for long-term treatment of GERD. In this context, it is relevant to
point out that the inclusion period of a trial comparing antireflux surgery with long-term
omeprazole treatment has just been completed, and the outcome of this trial will form a
comprehensive basis for future decision-making processes when dealing with the
long-term therapeutic strategy of GERD. A clear assessment of the role of surgery in
relation to medical therapy can come only from similar trials, in which entry and out-
come criteria are strictly defined, the study population is sufficiently large and the
patients are followed for at least five years. This is especially true, since available data in
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the literature contain results from studies comparing the outcome ofmedical and surgical
treatment, where the medical alternative is far from optimal and not updated.
The indications for antireflux surgery today are: patients with long-standing, well-
established, chronic gastroesophageal reflux disease requiring frequent intermittent
and/or continuous medical therapy to control symptoms and/or the esophageal lesions.
Severe complications in the form of strictures, Barrett's esophagus and respiratory com-
plications are generally approved of as being indications for antireflux surgery. Frequent
relapses in patients with a well established GERD are also the well-established indication
for long-term medical maintenance therapy. This means that the indications for
long-term medical and surgical therapy are essentially the same. In fact, it can be argued
that an adequate clinical response to a proton pump inhibitor is an important prerequisite
for a successful outcome after antireflux surgery, thereby taking the advantage of the
outcome of the short-term therapeutic effect of proton pump inhibitors as being a useful
diagnostic test for the disease [93]. This hypothesis must, however, be proven in future
clinical trials.
COMPARATIVE TRIALS
The only scientifically accepted way of establishing an eventual advantage of one
therapeutic principle over another is to carry out a comparative, randomized clinical trial.
There are a number of obstacles that make the design and logistics of similar trials com-
plicated. However, some studies have already been completed, and the short-term out-
come of these clearly favors the surgical alternative [90, 91, 92]. It is interesting to note
that in the Veteran Administration study [94], the total frequency ofcomplaints was fair-
ly similar in the surgical and medical treatment groups. In the medical treatment arm, the
complaints of reflux symptoms dominated, whereas in the surgical group, postfundopli-
cation symptoms of varying severity seem to be most predominating. Unfortunately for
the clinical decision process oftoday and the near future, the medical therapy applied in
the actual studies is not relevant. A trial comparing proton pump inhibitors and antireflux
surgery represents the treatment options oftoday and tomorrow.
EPIDEMIOLOGICAL SUPPORT IN THE PROCESS OF DECIDING
BETWEEN THE KNIFE AND THE PILL
National incidence and prevalence data have to be estimated from extensive inter-
view protocols and consequently subjected to either over- or underreporting [93-95]. The
percentage of patients with reflux symptoms found to have esophagitis (and therefore
having a firm diagnosis) at endoscopy varies from 20-75 percent depending on the selec-
tion process applied to the study population [96-97]. We need to examine large endo-
scopic series of patients to assess the true prevalence of esophagitis in the general gas-
troenterological practice. It seems, however, as ifesophagitis is seen at least as frequent-
ly as duodenal and gastric ulcers in the endoscopy suite, but the GERD is seldom a cause
of death (except postoperatively and postinterventionally) and rarely causes hospital
admission. According to Brunnen and co-workers [98], the annual mortality rate from
severe esophagitis was 0.1/100,000 from 1951-1967, but when the operative mortality
was considered, the total annual mortality rate rose to 0.16/100,000. In adults, the inci-
dence of reflux symptoms and esophagitis increases with age, and the disease severity
seems also to increase with age. More than half of the patients with Barrett's esophagus
who present themselves to an endoscopy unit are over 70 years of age, and up to two-
thirds of them have reported to have another reflux complication as well [99]. Among
patients with endoscopically verified esophagitis, a considerable number have concomi-
tant complicating medical disorders, which sometimes may call for greater attention than
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the GERD itself. It can be theoretically calculated that from a hypothetical group of 100
patients with symptomatic and endoscopically diagnosed GERD only 25 can be consid-
ered suitable for antireflux surgery depending on the different clinical considerations as
detailed above. Apparently, the great majority ofpatients with complicated reflux disease
are not fit for surgery and should, thus, only be managed medically. However, for
patients who do not present an increased surgical risk and who also have symptomatic,
severe GERD with or without esophagitis, antireflux surgery is still the gold standard to
which all future alternative therapeutic regimens should be compared. Provided that
antireflux surgery is performed with an optimal technique, the actual operative risk ofthe
patients should be the factor that determines the choice of therapy. The long-term conse-
quences of antireflux surgery on the quality of life in patients with GERD is impressive,
and in addition to that, the advantageous cost-effective ratio of surgery is obvious. In
fact, the cost of a laparoscopic fundoplication corresponds roughly to 2.5 years of main-
tenance medical therapy [100].
REFERENCES
1. Armstrong, D., Nicolet, M., Monnier, T., Chapuis, G., Savary, M., and Blum A.J. Maintenance
therapy: Is there still a place for antireflux surgery? World. J. Surg. 6:300, 1992.
2. Dent, J. Long-term aims of treatment of reflux disease, and the role of non-drug measures.
Digestion 51(Suppl 1):30-4, 1992.
3. Olbe, L. and Lundell, L. Medical treatment of reflux esophagitis. Hepato-gastroenterol.
39:322-324, 1992.
4. Bell, J.I.V. and Hunt R.H. Role ofgastric acid suppression in the treatment ofgastroesophageal
reflux disease. Gut 33:118-24, 1992;.
5. Bell, N.J.V., Burget, D., Howden, C.W., Wilkinson, J., and Hunt, R.H. Appropriate acid sup-
pression for the management of gastroesophageal reflux disease. Digestion 51:Suppl 1:59-67,
1992.
6. Dent, J., Yeomans, N.D., MacKinnon, M., Reed, W., Narielvala, F.M., Hetzel, D.J., and
Solcia, E. Omeprazole vs. ranitidine for prevention of relapse in reflux esophagitis: a con-
trolled double-blind trial oftheir efficacy and safety. Gut 35:590-598, 1994.
7. Hallerback, B., Unge, P., Carling, L., Edwin, B., Glise, H., Havu, N., Lyrenas, E., and
Lundberg, K. Omeprazole or ranitidine in long-term treatment of reflux esophagitis.
Gastroenterology 107:1305-1311, 1994.
8. Havelund, T., Laursen, L.S., Skoubo-Kristensen, E., Andersen, B.N., Pedersen, S.A., Jensen,
K.B., Fenger, C., Hanberg-Sorensen, F., Pedersen, S.A., Jensen, K.B., Fenger, C., Hanberg-
Sorensen, F., and Lauritsen, K. Omeprazole and ranitidine in treatment of reflux esophagitis:
double blind comparative trial. Brit. Med. J. 296:89-92, 1988.
9. Isal, J.B., Zeitun, B., Barbier, B., Cayphas, J.P., and Carlsson, R. Comparison of two dosage
regimens ofomeprazole-10 mg once daily and 20 mg week-ends-as prophylaxis against recur-
rence ofreflux esophagitis. Gastroenterology 98:A63, 1990.
10. Klinkenberg-Knol, E.C., Jansen, J.B.M.J., Festen, H.P.M., Meuwissen, S.G.M., and Lamers,
C.B.H.W. Double blind multicentre comparison of omeprazole and ranitidine in the treatment
ofreflux esophagitis. Lancet i:349, 1987.
11. Klinkenberg-Knol, E.C., Jansen, J.B.M.J., Lamers, C.B.H.W., Nelis, F., Snel, P., and
Meuwissen S.G. Use of omeprazole in the management of reflux esophagitis resistant to
H2-receptor antagonists. Scand. J. Gastroenterol. 24(Suppl 166):88-93, 1989.
12. Laursen, L.S., Bondesen, S., Hansen, J., Sanchez, G., Sebelin, E., Havelund, T., Fenger, C.,
and Lauritsen, K. Omeprazol 10 mg or 20 mg daily for the prevention of relapse in gastroe-
sophageal reflux disease? A double-blind comparative study. Gastroenterology 102:A109,
1992.
13. Lundell, L., Backman, L., Ekstrom, P., Enander, L.K., Fausa, O., Lind, T., Lonroth, H.,
Sandmark, S., Sandzen, B., and Unge, P. Omeprazole or high-dose ranitidine in the treatment
ofpatients with reflux esophagitis not responding to standard doses ofH2-receptor antagonists.
Aliment. Pharmacol. Ther. 4:145-55, 1990.
14. Lundell, L., Backman, L., Ekstrom, P., Enander, L.K., Falkmer, S., Fausa, O., Grimelius, L.,
Havu, N., Lind, T., and Conroth, H. Prevention of relapse and reflux esophagitis after endo-
scopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand. J.
Gastroenterol. 26:246-56, 1991.Lundell: Long-term treatment ofreflux 243
15. Marciano-D'Amore, D.A., Paterson, W.G., DaCosta, L.R., and Beck, I.T. Omeperazole in
H2-receptor antagonists resistant reflux esophagitis. J. Clin. Gastroenterol. 12:616-620, 1990.
16. Sandmark, S., Carlsson, R., Fausa, O., and Lundell, L. Omeprazole or ranitidine in the treat-
ment of reflux esophagitis: results of double-blind, randomized, Scandinavian multicenter
study. Scand. J. Gastroenterol. 23:625, 1988.
17. Sontag, S., Robinson, M., Roufail, W., Berman, R., Berlin, R., Berger, R., Simon, T., and
Cagliola, A. Daily dose of omeprazole (OME) is needed to maintain healing in erosive
esophagitis (EE). Am. J. Gastroenterol. 87:1258, 1992.
18 Van Trappen, G., Rutgeer, T.S.L., Schurmans, P., and Coenegrachts, J.L. Omeprazole (40 mg)
is superior to ranitidine in the short-term treatment of ulcerative reflux esophagitis. Dig. Dis.
Sci. 33:523, 1988.
19. Koelz, H.R. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs:
an analysis ofrandomized clinical trials. Scand. J. Gastroenterol. 24(Suppl 156):25-36, 1989.
20. Tytgat, G.N.J., Nio, C.U., and Schotborgh, R.H. Reflux esophagitis. Scand. J. Gastroenterol.
25(Suppl 175):1, 1990.
21. Tytgat, G.N.J., Anker-Hansen, O.J., Carling, L. de Groot, G.H., Geldof, H., Glise, H., Efskind,
P.L., Elsborg, L., Karvonen, A.L. and Ohlin, B. Effect of cisapride on relapse of reflux
esophagitis, healed with an antisecretory drug. Scand. J. Gastroenterol. 27:175-83, 1992.
22. Toussaint, J., Gussuin, A., Deruuttre, M., Huble, F., and Devis, G. Healing and prevention of
relapse ofreflux esophagitis by cisapride. Gut 32:1280-5, 1991.
23. Blum, A.L. and the EUROCIS-trialist. Cisapride reduces the relapse rate on reflux esophagitis.
Sydney, Australia:World Congress ofGastroenterology; 1990.
24. Lundell, L. Acid suppression in the long-term treatment ofpeptic stricture and Barrett's esoph-
agus. Digestion 51(Suppl. 1):49-58, 1992.
25. Fergusson, R., Dronfield, M.W., and Atkinson, M. Cimetidine in treatment of peptic stricture.
Brit. Med. J. 2:472-474, 1979.
26. Farup, P.G., Modalsli, B., Tholfsen, J.K., Efskind, P.S., Kildebo, S., and Lunde, O.C.
Ranitidine 300 mg once daily after dilatation of peptic esophageal strictures: a one-year place-
bo-controlled, follow-up study. Gastroenterology 102:A66, 1992.
27. Ching, C.K., Shaheen, M.Z., and Holmes, G.K. Is omeprazole more effective in the treatment
ofresistant reflux esophagitis and associated peptic strictures? Gastroenterology 98:A30, 1990.
28. Marks, R., Richter, J.E., Koehler, R., Spenney, J., and Mills, T. Does medical therapy improve
dysphagia in patients with peptic strictures and esophagitis? Gastroenterology 102:A118, 1992.
29. Deviere, J., Buset, M., Dumonceau, J.M., Rickaert, F., and Cremer, M. Regression of Barrett's
epithelium with omeprazole. N. Engl. J. Med. 320:1497-1498, 1989.
30. Gore, E.S., Healey, C.J., Sutton, R., Shepherd, N.A., and Wilkinson, S.P. Regression of colum-
nar lined (Barrett's) esophagus with continuous omeprazole therapy. Gastroenterology
102:A75, 1992.
31. Dent, J., Bremner, C.G., Collen, M.J., Haggitt, R.C., and Spechler, S.J. (Working party report
to the World Congress of Gastroenterology, Sidney 1990). Barrett's esophagus. J.
Gastroenterol. Hepatol. 6:1-22, 1990.
32. Lillemo, K.D., Johnson, L.F., and Harmon, J.W. Role of components of gastroduodenal con-
tents in experimental acid esophagitis. Surg. 92:276-284, 1982.
33. Kivilaakso, E., Fromm, D., and Silen, W. Effects ofbile salts and related compounds on isolat-
ed esophageal mucosa. Surg. 87:280-285, 1980.
34. Pellegrini, C.A., DeMeester, T.R., Wernly, J.A., Johnson, L.F., and Skinner, D.B. Alkaline
gastroesophageal reflux. Am. J. Surg. 135:177-184, 1978.
35. Attwood, S.E., DeMeester, T.R., Bremner, C.G., Barlow, A.P., and Hinder, R.A. Alkaline gas-
troesophageal reflux: implications in the development of complications in Barrett's columnar
lined lower esophagus. Surg. 106:764-770, 1989.
36. Sing, H.S., Bradley, L.A., and Richter, J.E. Determinants of esophageal alkaline pH environ-
ment in controls and patients with gastroesophageal reflux disease. Gut 34:309-316, 1993.
37. Stein, H.J., Barlow, A.P., DeMeester, T.R., and Hinder, R.A. Complications of gastroe-
sophageal reflux disease: role of the lower esophageal sphincter. Esophageal acid and
acid/alkaline exposure and duodenogastric reflux. Ann. Surg. 216:35-43, 1992.
38. Champion, G., Singh, S., Bechi, P., and Richter, J.E. Duodenogastric reflux relationship to
esophageal pH and response to omeprazole. Gastroenterology 104:A51, 1993.
39. Sampliner, R.E. Antireflux surgery and Barrett's esophagus regression: wheel or fortune or to
tell the truth? Am. J. Gastroenterol. 86:645-646, 1991.244 Lundell: Long-term treatment ofreflux
40. Williamson, A., Ellis, F.H., and Gibb, S.P. Effect of anti-reflux operation on Barrett's mucosa.
Ann. Thoracic. Surg. 49:537-542, 1990.
41. Colin-Jones, D.G., Langman, M.J.S., and Lawson, D.H. Postmarketing surveillance of the
safety ofcimetidine: 10 year mortality report. Gut 33:1280-1284, 1992.
42. Joelsson, S., Joelsson, I.B., Lundborg, B., Walan, A., and Wallander, M.A. Safety experience
from long-term treatment with omeprazole. Digestion 51(Suppl. 1):93-101, 1992.
43. Lind, T., Cederberg, C., Idstrom, J.P., Lonroth, H., Olbe, L., and Lundell, L. 24-hour intragas-
tric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in
patients with reflux esophagitis. Scand. J. Gastroenterol. 26:620-626, 1991.
44. Solcia, E., Fiocca, R., Havu, N., Dalvag, A., and Carlsson, R. Gastric endocrine cells and gas-
tritis in patients receiving long-term omeprazole treatment. Digestion 51(Suppl. 1):82-91,
1992.
45. Dent, J., Yeomans, N.D. Acid related diseases: improving the treatment options. Digestion
51(Suppl. 1):13-21, 1992.
46. Jamieson, G.G., Duranceau, A.C., and Deschamps, C. Surgical treatment of gastroesophageal
reflux disease. In: Jamieson, G.G., Duranceau, A.C., eds. Gastresophageal reflux.
Philadelphia:W.B. Saunders; 1988.
47. Ireland, A.C., Holloway, R.H., Toouli, J., and Dent, J. Mechanisms underlying the antireflux
action offundoplication. Gut 34:303, 1993.
48. Holloway, R.H. and Dent, J. Lower esophageal sphincter dysfunction in gastroesophageal
reflux disease. Gastroenterol. Clin. N. Am. 19:517, 1990.
49. Bancewicz, J., Mughal, M., and Marples, M. The lower esophageal sphincter after floppy
Nissen fundoplication. Brit. J. Surg. 74:162, 1987.
50. Bjerkeset, T., Nordgard, K., and Schjonsby, H. Effect of Nissen fundoplication operation on
the competence ofthe lower esophageal sphincter. Scand. J. Gastroenterol. 15:213, 1980.
51. DeMeester, T.R., Wernly, J.A., Brian, G.H., Little, A.G., and Skinner, D.B. Clinical and in
vitro analysis of determinants of gastroesophageal competence: A study of the principles of
antireflux surgery. Am. J. Surg. 137:39, 1979.
52. Johansson, J., Johnson, F., Joelsson, B.E., Floren, C.H., and Walther, B. Outcome from five
years after 3600 fundoplication for gastroesophageal reflux disease. Brit. J .Surg. 80:46, 1993.
53. Lundell, L., Abrahamsson, H., Ruth, M., Sandberg, N., and Olbe, L. Lower esophageal sphinc-
ter characteristics and esophageal acid exposure following partial or 3600 fundoplication:
Results ofa prospective, randomized, clinical study. World J. Surg. 15:115, 1991.
54. Mughal, M.M., Bancewicz, J., and Marpels, M. Oesophageal manometry and pH recording
does not predict the bad results ofNissen fundoplication. Brit. J. Surg. 77:43-45, 1990.
55. Little, A.G. Mechanism of action of antireflux surgery: theory and facts. World. J. Surg.
16:320, 1992.
56. Allison, B.R. Refluxesophagitis, sliding hiatal hernia and the anatomy of repair. Surg.
Gynecol. Obstet. 92:419, 1951.
57. Allison, B.R. Hiatus hernia: a 20 year retrospective survey. Ann. Surg. 178:273, 1973.
58. Nissen, R. Eine einfache Operation zur Beeinflussung der Refluxosophagitis. Schw. Med.
Wochenschr. 86:590-592, 1956.
59. Clark, J. Hiatal hernia and reflux esophagitis. In: Hennessy, T.B.J. and Cuschieri, A., eds.
Surgery ofthe esophagus. London:Bailliere Tindal; 1986.
60. Rossetti, N. and Hell, K. Fundoplication for treatment of gastroesophageal reflux disease in
hiatal hernia. World. J. Surg. 1:439, 1977.
61. Russel, C.O.H., Pope, C.H.E., Gannan, R.M., Allen, F.D., Velasco, N., and Hill, L.D. Does
surgery correct esophageal motor dysfunction in gastresophageal reflux? Ann. Surg. 194:290,
1981.
62. DeMeester, T.R., Johnson, L.F., and Kent, A.H. Evaluation of current operations for the pre-
vention ofgastroesophageal reflux. Ann. Surg. 180:511, 1974.
63. Gear, M.W.L., Gillison, E.W., and Dowling, B.L. Randomized prospective trial of the
Angelchik antireflux prosthesis. Brit. J. Surg. 71:681, 1984.
64. Kimiot, W.A., Kirby, R.M., Akinola, D., and Temple, G. Prospective randomized trial of
Nissen fundoplication and Angelchik prosthesis in the surgical treatment ofmedically refracto-
ry gastroesophageal reflux disease. Brit. J. Surg. 78:1181, 1991.
65. Stuart, R.C., Dawson, K., Keeling, P., Byrne, P.J., and Hennessy, T.P.J. A prospective random-
ized trial ofAngelchik prosthesis versus Nissen fundoplication. Brit. J. Surg. 76:86, 1989.
66. Thor, K.B.A. and Silander, T. A long-term randomized prospective trial of the Nissen proce-
dure versus a modified Toupet technique. Ann. Surg. 210:719, 1989.Lundell: Long-tern treatment ofreflux 245
67. Walker, S.J., Holt, S., Sanderson, C.J., and Stoddard, C.J. Comparison ofNissen total and Lind
partial transabdominal fundoplication in the treatment ofgastroesophageal reflux. Brit. J. Surg.
79:410, 1992.
68. Washer, B.F., Gear, M.W.L., Dowling, B.L., Gillison, E.W., Royston, C.M., and Spencer, J.
Randomized prospective trial of Roux-en-Y duodenal diversion vs. fundoplication for severe
reflux esophagitis. Brit. J. Surg. 71: 181, 1984.
69. Jamieson, G.G., Watson, D.I., Britten-Jones, R., Mitchell, P.C., and Anvari, M. Laparoscopic
Nissen Fundoplication. Ann. Surg. 2:137-145, 1994.
70. Cadiere, G.B., Houben, J.J., Bruyns, J., Himpens, J., Panzer, J.M., and Gelin, M. Laparoscopic
Nissen fundoplication: technique and preliminary results. Brit. J. Surg. 81:400-403, 1994.
71. Durrans, D., Armstrong, C.P., and Taylor, T.V. The Angelchik anti-reflux prosthesis-some
reservations. Brit. J. Surg. 72:525, 1985.
72. Garstin, W.I., Hohnston, G W., Kennedy, T.L., and Spencer, E.S. Nissen fundoplication: the
unhappy 15 percent. J. Royal Coll. Surg., Edinburgh, 31:207, 1986.
73. Negre, J.B. Post-fundoplication symptoms. Do they restrict the success of Nissen fundoplica-
tion? Ann. Surg. 198:698, 1983.
74. Lundell, L.R., Myers, J.C., and Jamieson, G.G. Gastric emptying and its relationship to symp-
toms of"gas bloat" after antireflux surgery. Eur. J. Surg. 160:161-166, 1993.
75. Low, D.E., Anderson, R.P., Ilves, R., Ricciadelli, E., and Hill, L.D. 15-20 years results after
the Hill antireflux operation. J. Thorac. Cardiovasc. Surg. 98:444, 1989.
76. Matikainen, M. Nissen-Rossetti fundoplication for the treatment of gastroesophageal reflux.
Acta Chir. Scand. 148:173, 1982.
77. Negre, S.B., Markkula, H.T., Keyrilainen, O., and Matikainen, M. Nissen fundoplication. Am.
J. Surg. 146:635, 1983.
78. Shirazi, S.S., Schulze, K., and Soper, R.T. Long term follow-up for treatment of complicated
chronic reflux esophagitis. Arch. Surg. 122:548, 1987.
79. DeMeester, T.R., Bonavina, L., and Albertucci, M. Nissen fundoplication for gastroesophageal
reflux disease. Evaluation of primary repair in 100 consecutive patients. Ann. Surg. 204:9,
1986.
80. DeMeester, T.R. and Stein, H.J. Minimizing the side effects of antireflux surgery. World. J.
Surg. 16:335, 1992.
81. Donahue, P.E., Samuelson, S., Nyhus, L.M., and Bombeck, C.T. The floppy Nissen fundopli-
cation. Arch. Surg. 120:663, 1985.
82. Hill, L.D., Ilves, R., Stevenson, J.K., and Pearson, J.M. Reoperation for disruption and recur-
rence after Nissen fundoplication. Arch. Surg. 114:542, 1979.
83. Leonardi, H.K., Corzier, R.E., and Ellis, F.H. Reoperation for complications ofthe Nissen fun-
doplication. J. Thorac. Cardiovasc. Surg. 81:50, 1989.
84. Maher, J.W., Hocking, M.P., and Woodward, E.R. Reoperations for esophagitis following
failed antireflux procedures. Ann. Surg. 201:723, 1985.
85. Moher, J.W., Hocking, M.B., and Woodward, E.R. Reoperations for esophagitis following
Nissen antireflux procedures. Ann. Surg. 201:723, 1985.
86. Mughal, M.M., Bancewicz, J., and Marpels, M. Oesophageal manometry and pH recording
does not predict the bad results ofNissen fundoplication. Brit. J. Surg. 77: 43, 1990.
87. Skinner, D.B. Surgical management after failed antireflux operations. World J. Surg. 16:359,
1992.
88. Siewert, R J., Isolauri, J., and Feussner, H. Reoperation following failed fundoplication. World
J. Surg. 13:791, 1989.
89. Feussner, H., Petri, A., Walker, S., Bollschweiler, E., and Siewert, J.R. The modified
AFP-score: an attempt to make the results of antireflux surgery comparable. Brit. J. Surg.
78:942, 1991.
90. Behar, J., Sheahan, D.G., Biancani, P., Spiro, H.M., and Storer, E.H. Medical and surgical
management ofreflux esophagitis: a 38-month report on a prospective clinical trial. N. Engl. J.
Med. 293:263-268, 1975.
91. Johansson, K.-E. and Tibbling, L. Maintenance treatment with ranitidine compared with fundo-
plication in gastroesophageal reflux disease. Scand. J. Gastroenterol. 21:779, 1986.
92. Spechler, J.S. et al. Comparison of medical and surgical therapy for complicated gastroe-
sophageal reflux disease in veterans. N. Engl. J. Med. 326:786-792, 1992.
93. Young, M.F., Sanowski, R.A., Talbert, G.A., Harrison, M.E., and Walker, B.E. Omeprazol
administration as a test for gastroesophageal reflux. Gastroenterology 102:A192, 1992.246 Lundell: Long-term treatment ofreflux
94. Weinbeck, M. and Barnert, J. Epidemiology of reflux disease and reflux esophagitis. Scand. J.
Gastroenterol. 24(Suppl. 156):7-13, 1989.
95. Howard, P.J. and Heading, R.C. Epidemiology of gastroesophageal reflux disease. World J.
Surg. 16:288-293, 1992.
96. Loof, L., Gotell, P., and Elfberg, B. The incidence of reflux esophagitis. Scand. J.
Gastroenterol. 28:113-118, 1993.
97. Johnsen, R., Bernersen, B., Straume, B., Forde, O.H., Bostad, L., and Burhol., P.G.
Prevalences ofendoscopic and histological findings in subjects with or without dyspepsia. Brit.
Med. J. 302:749, 1991.
98. Brunnen, P.L., Karmody, A.M., and Needham, C.D. Severe peptic esophagitis. Gut
10:831-837, 1969.
99. Heading, R.C. Epidemiology of esophageal reflux disease. Scand. J. Gastroenterol. 24(suppl.
168):33, 1989.
100. Coley, C.M., Barry, M.J., Spechler, S.J., Williford, W.O., and Mulley, A.G. Initial medical
vs. surgical therapy for complicated chronic gastroesophageal reflux disease (GERD).
Gastroenterology 104:A5, 1993.